Effect of sacubutril/valsartan on Tp-e, QT, QTc, Tp-e/QTc parameters in heart failure with reduced ejection fraction

Ahmet Genç; Gülsüm Meral Yılmaz Öztekin

Makale detayları

Effect of sacubutril/valsartan on Tp-e, QT, QTc, Tp-e/QTc parameters in heart failure with reduced ejection fraction

Yazarlar:

Ahmet Genç | Gülsüm Meral Yılmaz Öztekin

Yayıncı:

Cukurova University

Ana Başlıklar:

Kalp ve Damar Cerrahisi

Dergi:

Cukurova Medical Journal Vol.49 Issue 1, pp.47-53

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314668

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: The purpose of this study is to evaluate ventricular repolarization before, at the first month, and sixth month after SacubutrilValsartan, an angiotensin receptor neprilysin inhibitor ARNI treatment in heart failure patients with reduced ejection fraction HFrEF. Materials and Methods: We included 49 patients with HFrEF who switched to ARNI therapy. The 12-lead electrocardiography ECG was evaluated before ARNI therapy and also during the first and sixth months of the therapy. We evaluated demographic, clinical, and laboratory parameters, as well as medications and ECG data, including heart rate. Additionally, we examined QT, QTc, Tp-e, Tp-e calculated Tp-ec, Tp-ecQTc, Tp-eQT, and Tp-eQTc. Results: After receiving ARNI treatment, ventricular repolarization indices were significantly reduced in the first and sixth months compared to before treatment. Specifically, the QTc values decreased from 457.6 ms to 443.8 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.190.03. Additionally, the QTc values decreased from 457.6 ms to 444.9 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.180.03. However, when the first and sixth months under ARNI treatment were compared, no significant difference was found QTc: 443.8 ms vs. 444.9 ms, Tp-eQT: 0.190.03 vs. 0.180.003. Conclusion: ARNI treatment in HFrEF positively affected QTc, Tp-e, and Tp-ec intervals and Tp-eQT, Tp-eQTc, and Tp-ecQTc ratios, which are indicators of ventricular repolarization. Moreover, this effect started in the first month and continued in the sixth month.

 Purpose: The purpose of this study is to evaluate ventricular repolarization before, at the first month, and sixth month after SacubutrilValsartan, an angiotensin receptor neprilysin inhibitor ARNI treatment in heart failure patients with reduced ejection fraction HFrEF. Materials and Methods: We included 49 patients with HFrEF who switched to ARNI therapy. The 12-lead electrocardiography ECG was evaluated before ARNI therapy and also during the first and sixth months of the therapy. We evaluated demographic, clinical, and laboratory parameters, as well as medications and ECG data, including heart rate. Additionally, we examined QT, QTc, Tp-e, Tp-e calculated Tp-ec, Tp-ecQTc, Tp-eQT, and Tp-eQTc. Results: After receiving ARNI treatment, ventricular repolarization indices were significantly reduced in the first and sixth months compared to before treatment. Specifically, the QTc values decreased from 457.6 ms to 443.8 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.190.03. Additionally, the QTc values decreased from 457.6 ms to 444.9 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.180.03. However, when the first and sixth months under ARNI treatment were compared, no significant difference was found QTc: 443.8 ms vs. 444.9 ms, Tp-eQT: 0.190.03 vs. 0.180.003. Conclusion: ARNI treatment in HFrEF positively affected QTc, Tp-e, and Tp-ec intervals and Tp-eQT, Tp-eQTc, and Tp-ecQTc ratios, which are indicators of ventricular repolarization. Moreover, this effect started in the first month and continued in the sixth month.

 Purpose: The purpose of this study is to evaluate ventricular repolarization before, at the first month, and sixth month after SacubutrilValsartan, an angiotensin receptor neprilysin inhibitor ARNI treatment in heart failure patients with reduced ejection fraction HFrEF. Materials and Methods: We included 49 patients with HFrEF who switched to ARNI therapy. The 12-lead electrocardiography ECG was evaluated before ARNI therapy and also during the first and sixth months of the therapy. We evaluated demographic, clinical, and laboratory parameters, as well as medications and ECG data, including heart rate. Additionally, we examined QT, QTc, Tp-e, Tp-e calculated Tp-ec, Tp-ecQTc, Tp-eQT, and Tp-eQTc. Results: After receiving ARNI treatment, ventricular repolarization indices were significantly reduced in the first and sixth months compared to before treatment. Specifically, the QTc values decreased from 457.6 ms to 443.8 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.190.03. Additionally, the QTc values decreased from 457.6 ms to 444.9 ms, and the Tp-eQT ratio decreased from 0.210.03 to 0.180.03. However, when the first and sixth months under ARNI treatment were compared, no significant difference was found QTc: 443.8 ms vs. 444.9 ms, Tp-eQT: 0.190.03 vs. 0.180.003. Conclusion: ARNI treatment in HFrEF positively affected QTc, Tp-e, and Tp-ec intervals and Tp-eQT, Tp-eQTc, and Tp-ecQTc ratios, which are indicators of ventricular repolarization. Moreover, this effect started in the first month and continued in the sixth month.

 yetersizliği HFrEF hastalarında SakubutrilValsartan-Anjiyotensin reseptör neprilisin inhibitörünün ARNI tedavisi öncesi, tedavi sonrası birinci ve altıncı aylarda ventriküler repolarizasyonu değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmaya anjiyotensin dönüştürücü enzim inhibitörlerinden veya anjiyotensin reseptör blokerlerinden ACE-IARB ARNI tedavisine geçen 49 HFrEF hastası dahil edildi. ARNI tedavisi öncesinde, birinci ve altıncı aylarda 12 derivasyonlu elektrokardiyografi EKG değerlendirildi. Demografik, klinik ve laboratuvar parametrelerinin yanı sıra ilaçlar ve EKG verileri, kalp atış hızı, QT, QTc, Tp-e, hesaplanan Tp-e Tp-ec, Tp-ecQTc, Tp-eQT ve Tp-eQTc değerlendirildi. Bulgular: ARNI tedavisi aldıktan sonra ventriküler repolarizasyon indekslerinde tedavi öncesine göre birinci ve altıncı ayda anlamlı azalma görüldü. Spesifik olarak QTc değerleri 457.6 msden 443.8 msye, Tp-eQT oranı ise 0.210,03ten 0.190.03e düştü. Ayrıca QTc değerleri 457.6 msden 444.9 msye, Tp-eQT oranı ise 0.210.03ten 0.180.03e düştü. Ancak ARNI tedavisi altında birinci ve altıncı aylar karşılaştırıldığında anlamlı fark saptanmadı QTc: 443.8 ms vs. 444.9 ms, Tp-eQT: 0.190.03 vs. 0.180.003. Sonuç: HFrEFde ARNI tedavisi ile ventriküler repolarizasyonun göstergeleri olan QTc, Tp-e ve Tp-ec aralıklarında ve Tp-eQT, Tp-eQTc ve Tp-ecQTc oranlarında olumlu etkilendi. Üstelik bu etki 1. ayda başlayıp 6. ayda da devam etti.

Makale detayları

Effect of sacubutril/valsartan on Tp-e, QT, QTc, Tp-e/QTc parameters in heart failure with reduced ejection fraction

Yazarlar:

Ahmet Genç | Gülsüm Meral Yılmaz Öztekin

Yayıncı:

Cukurova University

Ana Başlıklar:

Kalp ve Damar Cerrahisi

Dergi:

Cukurova Medical Journal Vol.49 Issue 1, pp.47-53

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314668

pISSN:

2602-3032

Angiotensin receptor neprilysin inhibitor

Tp-e

Tp-e/QTc ratio

QTc

Sudden cardiac death

Ventricular repolarizationAni kardiyak ölüm

Anjiyotensin reseptörü neprilisin inhibitörü

Tp-e; Tp-e/QTc oranı; QTc

Ventriküler repolarizasyon.

Sayı

Makale detayları

Yazarlar: Ahmet Genç | Gülsüm Meral Yılmaz Öztekin

Yayıncı: Cukurova University

Ana Başlıklar: Kalp ve Damar Cerrahisi

Dergi: Cukurova Medical Journal Vol.49 Issue 1, pp.47-53

Belge Tipi: Makale

Yayın Tarihi: 3/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001314668

pISSN: 2602-3032

Sayı

Yazarlar:

Ahmet Genç | Gülsüm Meral Yılmaz Öztekin

Yayıncı:

Cukurova University

Ana Başlıklar:

Kalp ve Damar Cerrahisi

Dergi:

Cukurova Medical Journal Vol.49 Issue 1, pp.47-53

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314668

pISSN:

2602-3032